Rhenman & Partners Asset Management AB lifted its position in Humana Inc. (NYSE:HUM - Free Report) by 78.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,230 shares of the insurance provider's stock after acquiring an additional 24,230 shares during the quarter. Humana accounts for approximately 1.4% of Rhenman & Partners Asset Management AB's investment portfolio, making the stock its 28th largest holding. Rhenman & Partners Asset Management AB's holdings in Humana were worth $14,012,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of HUM. FPC Investment Advisory Inc. purchased a new stake in shares of Humana during the fourth quarter valued at about $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana in the 4th quarter valued at $30,000. LFA Lugano Financial Advisors SA grew its position in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after acquiring an additional 45 shares during the period. OFI Invest Asset Management acquired a new position in shares of Humana during the 4th quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. grew its position in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after purchasing an additional 60 shares during the period. Hedge funds and other institutional investors own 92.38% of the company's stock.
Humana Price Performance
Shares of NYSE:HUM traded up $1.89 during trading on Thursday, hitting $287.42. 792,929 shares of the stock were exchanged, compared to its average volume of 1,740,090. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The company has a market cap of $34.69 billion, a PE ratio of 28.89, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a fifty day moving average price of $265.60 and a two-hundred day moving average price of $270.92. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.
Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, analysts forecast that Humana Inc. will post 16.47 EPS for the current year.
Humana Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date is Friday, March 28th. Humana's dividend payout ratio (DPR) is presently 35.58%.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on HUM. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Piper Sandler boosted their target price on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research report on Wednesday, January 15th. JPMorgan Chase & Co. dropped their price target on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research note on Tuesday, February 18th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Finally, Guggenheim began coverage on Humana in a report on Wednesday. They set a "buy" rating and a $326.00 price objective on the stock. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Humana presently has an average rating of "Hold" and an average price target of $284.25.
View Our Latest Stock Report on HUM
Humana Profile
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
